BCR-ABL inhibitor
Catalog No. A03-901
Catalog No. | Pack Size | Price (USD) | |
---|---|---|---|
A03-901-10 | 10 mg | $45 | |
A03-901-50 | 50 mg | $150 | |
A03-901-BULK | BULK | Contact Us |
Overview:
A novel, selective BCR-ABL inhibitor. More potent than imatinib against wild-type BCR-ABL (IC50 < 30 nM) (1). Induces apoptosis (2).
References:
1. E Weisberg et al. Br. J. Cancer 2006 94:1765
2. S Verstovsek et al. Leuk. Res. 2006 30:1499
CAS Registry Number:
641571-10-0
Molecular Formula:
C28H22F3N7O
Appearance:
Off-white powder
Melting Point:
N/A
Molecular Weight:
529.5
Purity:
>98% (TLC); NMR (Conforms)
Solubilization:
May be dissolved in DMSO (50 mg/ml)
Aliases:
1. 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)- 5-(trifluoromethyl) phenyl]-3- [(4-pyridin-3-ylpyrimidin-2-yl) amino] benzamide
2. AMN-107
Storage and Stability:
Store desiccated as supplied at -20oC for up to 2 years. Store solutions at -20oC for up to 1 month.
Molecular Structure:
There are no related publications available for this product.
Cancer
STAY CONNECTED
Fax: 1-604-232-4601